Details for Patent: 9,193,732
Which drugs does patent 9,193,732 protect, and when does it expire?
Patent 9,193,732 protects KISQALI and KISQALI FEMARA CO-PACK (COPACKAGED) and is included in two NDAs.
Protection for KISQALI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-five patent family members in twenty-six countries.
Summary for Patent: 9,193,732
| Title: | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| Abstract: | This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same. |
| Inventor(s): | John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena |
| Assignee: | Astex Therapeutics Ltd , Novartis Pharmaceuticals Corp , Novartis Institutes for Biomedical Research Inc |
| Application Number: | US13/882,353 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,193,732 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 9,193,732
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | KISQALI | ribociclib succinate | TABLET;ORAL | 209092-001 | Mar 13, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Novartis | KISQALI FEMARA CO-PACK (COPACKAGED) | letrozole; ribociclib succinate | TABLET;ORAL | 209935-001 | May 4, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,193,732
| PCT Information | |||
| PCT Filed | November 09, 2011 | PCT Application Number: | PCT/US2011/059890 |
| PCT Publication Date: | May 18, 2012 | PCT Publication Number: | WO2012/064805 |
International Family Members for US Patent 9,193,732
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 083797 | ⤷ Start Trial | |||
| Argentina | 117799 | ⤷ Start Trial | |||
| Australia | 2011326620 | ⤷ Start Trial | |||
| Australia | 2016203534 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
